Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Daxibotulinumtoxina→

Daxibotulinumtoxina Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
93384-43-1
Molecular formula
C6708H10359N1729O1995S32
Molecular weight
148171.53 g/mol
Drug class
Botulinum neurotoxin type Along-acting neuromuscular blocking biologic
Mechanism of action
Enters cholinergic nerve terminals and cleaves SNAP-25, a presynaptic SNARE protein required for acetylcholine-vesicle fusion, thereby inhibiting acetylcholine release and producing temporary chemodenervation of the injected muscle.
Indications / reported uses
  • Temporary improvement in moderate-to-severe glabellar lines in adults
  • Treatment of cervical dystonia in adults; product-specific potency units are not interchangeable with other botulinum toxin products

Sources: US DailyMed — DAXXIFY prescribing information · FDA product label · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Daxibotulinumtoxina Environmental Risk Assessment (ERA) (the Daxibotulinumtoxina ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.